Management of antithrombotic agents during emergency endoscopy for upper gastrointestinal bleeding

Management of antithrombotic agents during emergency endoscopy for upper gastrointestinal bleeding - Management of antithrombotics for UGIB

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053561

Enrollment

389

Registered

2024-02-07

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper gastrointestinal bleeding

Interventions

Following the completion of the emergency endoscopic procedure to halt bleeding, every individual patient who was taking antithrombotic agents (Group A) immediately resumed their respective antithromb

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals aged over 20 years presenting with suspected UGIB necessitating urgent endoscopic intervention; those who received endoscopic hemostasis within 24 hours of the initial symptoms; and patients who were conscious with stable respiratory and cardiovascular functions.

Exclusion criteria

Exclusion criteria: Exclusions were applied to patients who required endotracheal intubation, those with unstable respiratory and circulatory systems impeding emergency endoscopic procedures, and cases with incomplete data.

Design outcomes

Primary

Measure	Time frame
The success rate of endoscopic hemostasis	—

Countries

Japan

Contacts

Public ContactYamaguchi Daisuke

National Hospital Organization Ureshino Medical Center Gastroenterology

daisukehawks@gmail.com0954431120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026